David Steinberg
Stock Analyst at Jefferies
(2.87)
# 1,481
Out of 5,182 analysts
34
Total ratings
64%
Success rate
26.11%
Average return
Main Sectors:
Top Industries:
Stocks Rated by David Steinberg
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BHC Bausch Health Companies | Downgrades: Hold | $12 → $8 | $5.64 | +41.84% | 7 | Feb 6, 2025 | |
| PRGO Perrigo Company | Upgrades: Buy | $45 → $63 | $11.64 | +441.24% | 8 | Sep 30, 2021 | |
| SUPN Supernus Pharmaceuticals | Upgrades: Buy | $25 → $40 | $49.19 | -18.68% | 11 | Apr 13, 2021 | |
| JAZZ Jazz Pharmaceuticals | Maintains: Buy | $151 → $188 | $212.26 | -11.43% | 5 | Oct 9, 2020 | |
| OCUL Ocular Therapeutix | Initiates: Buy | $8 | $9.71 | -17.61% | 1 | Mar 17, 2020 | |
| OPTN Option Therapeutics | Initiates: Buy | $405 | $9.60 | +4,118.75% | 1 | Nov 7, 2017 | |
| SVRA Savara | Initiates: Buy | $20 | $5.25 | +280.95% | 1 | Sep 22, 2017 |
Bausch Health Companies
Feb 6, 2025
Downgrades: Hold
Price Target: $12 → $8
Current: $5.64
Upside: +41.84%
Perrigo Company
Sep 30, 2021
Upgrades: Buy
Price Target: $45 → $63
Current: $11.64
Upside: +441.24%
Supernus Pharmaceuticals
Apr 13, 2021
Upgrades: Buy
Price Target: $25 → $40
Current: $49.19
Upside: -18.68%
Jazz Pharmaceuticals
Oct 9, 2020
Maintains: Buy
Price Target: $151 → $188
Current: $212.26
Upside: -11.43%
Ocular Therapeutix
Mar 17, 2020
Initiates: Buy
Price Target: $8
Current: $9.71
Upside: -17.61%
Option Therapeutics
Nov 7, 2017
Initiates: Buy
Price Target: $405
Current: $9.60
Upside: +4,118.75%
Savara
Sep 22, 2017
Initiates: Buy
Price Target: $20
Current: $5.25
Upside: +280.95%